Patents Assigned to ML Laboratories
  • Biologically active materials
    Patent number: 6338843
    Abstract: A polymer-drug conjugate, in which the polymer is the polysaccharide dextrin, linked directly or indirectly to the drug, is effective to deliver the drug to a target site and is biodegradable. The conjugate may be prepared by succinoylating dextrin followed by reaction with the drug or a derivative thereof.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: January 15, 2002
    Assignee: ML Laboratories
    Inventors: Ruth Duncan, James Cassidy, Lisa German, Dale Hirst
  • Antiviral agent comprising CD4 and H2 histone
    Patent number: 5714462
    Abstract: The invention provides an agent against HIV and/or related viruses, comprising CD4 or a CD4-like substance and an H2 histone or an H2 histone-like protein. The content of the CD4 or CD4-like substance is preferably less than the antivirally effective dose of that substance alone. The invention also provides an H2 histone or an H2-like protein, for use in a method of medical treatment, in particular against HIV and/or related viruses, and also for use in the manufacture of a pharmaceutical composition against HIV and/or related viruses.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: February 3, 1998
    Assignee: ML Laboratories
    Inventors: Donald Selwyn Davies, Sunil Shaunak, Nigel John Gooderham, Robert John Edwards
  • Dextrin sulfates as anti HIV-1 agents and composition thereof
    Patent number: 5439892
    Abstract: The invention provides an agent against HIV-1 and related viruses, the agent being or including dextrin sulphate containing at most two sulphate groups per glucose unit. The invention also provides a composition containing such an agent, and the use of the agent or composition against HIV-1 and related viruses. By restricting the degree of substitution of the dextrin sulphate to a maximum of 2, the invention makes it possible to produce a dextrin sulphate having adequate anti-HIV activity while maintaining toxicity within acceptable limits.
    Type: Grant
    Filed: June 22, 1993
    Date of Patent: August 8, 1995
    Assignee: ML Laboratories
    Inventor: Donald S. Davies